Literature DB >> 17425384

Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray-based study.

Atul Bhardwaj1, William L Marsh, Jason W Nash, Catalin C Barbacioru, Susie Jones, Wendy L Frankel.   

Abstract

CONTEXT: Immunohistochemical stains have been used for the distinction of pancreatic adenocarcinoma from chronic pancreatitis.
OBJECTIVE: To determine if a double stain for MUC/p53 improved specificity and sensitivity for distinction of pancreatic adenocarcinoma from chronic pancreatitis by comparing maspin, mucin 4 (MUC4), p53, Smad4, and the double stain MUC4/p53.
DESIGN: Seventy-four pancreatic adenocarcinomas and 19 chronic pancreatitis cases were retrieved from archival files. Tissue cores were arrayed to create a tissue microarray of 2-mm cores. Sections were stained with antibodies against maspin, MUC4, p53, and Smad4. Additionally, a 2-color, double stain for MUC4 and p53 was developed and evaluated. Five percent or greater staining in either of the cores was considered positive. Intensity (0, 1, 2) and extent (%) of tumor cells staining was also determined.
RESULTS: The sensitivity for distinction of pancreatic adenocarcinoma from chronic pancreatitis with maspin, MUC4, p53, and Smad4 was 90%, 77%, 60%, and 63%, respectively; the specificity was 67%, 78%, 88%, and 88%, respectively. When MUC4 and p53 were combined in a double stain, and positive staining for either considered a positive result, the sensitivity increased to 96% but specificity was 73%. When immunoreactivity for both antibodies was necessary for a positive result, sensitivity fell to 39% but specificity was 100%. No correlation was found between intensity or extent of staining with any of the individual stains and tumor differentiation.
CONCLUSION: The double immunohistochemical stain for MUC4/p53 can be a useful diagnostic tool in conjunction with the hematoxylin-eosin-stained section for pancreatic adenocarcinoma, particularly when limited tumor is available for multiple stains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425384     DOI: 10.5858/2007-131-556-DISWPI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  11 in total

1.  Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.

Authors:  Sabrina C Sopha; Purva Gopal; Nipun B Merchant; Frank L Revetta; David V Gold; Kay Washington; Chanjuan Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

2.  Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases.

Authors:  Subhankar Chakraborty; Benjamin J Swanson; Neelima Bonthu; Surinder K Batra
Journal:  J Clin Pathol       Date:  2010-07       Impact factor: 3.411

3.  Staining for p53 and Ki-67 increases the sensitivity of EUS-FNA to detect pancreatic malignancy.

Authors:  Alexander W Jahng; Sonya Reicher; David Chung; Donna Varela; Rahul Chhablani; Anil Dev; Binh Pham; Jose Nieto; Rose J Venegas; Samuel W French; Bruce E Stabile; Viktor E Eysselein
Journal:  World J Gastrointest Endosc       Date:  2010-11-16

Review 4.  Current status of molecular markers for early detection of sporadic pancreatic cancer.

Authors:  Subhankar Chakraborty; Michael J Baine; Aaron R Sasson; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2010-10-01

5.  Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.

Authors:  Chanjuan Shi; Nipun Merchant; Guy Newsome; David M Goldenberg; David V Gold
Journal:  Arch Pathol Lab Med       Date:  2014-02       Impact factor: 5.534

6.  Breast carcinomatous tumoral emboli can result from encircling lymphovasculogenesis rather than lymphovascular invasion.

Authors:  Sepi Mahooti; Kyle Porter; Mary L Alpaugh; Yin Ye; Yi Xiao; Susie Jones; Joseph D Tellez; Sanford H Barsky
Journal:  Oncotarget       Date:  2010-06

7.  Ex vivo culture of intact human patient derived pancreatic tumour tissue.

Authors:  John Kokkinos; George Sharbeen; Koroush S Haghighi; Rosa Mistica C Ignacio; Chantal Kopecky; Estrella Gonzales-Aloy; Janet Youkhana; Paul Timpson; Brooke A Pereira; Shona Ritchie; Elvis Pandzic; Cyrille Boyer; Thomas P Davis; Lisa M Butler; David Goldstein; Joshua A McCarroll; Phoebe A Phillips
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

8.  Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis.

Authors:  Shunda Wang; Lei You; Menghua Dai; Yupei Zhao
Journal:  Ann Transl Med       Date:  2021-02

9.  Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours.

Authors:  Arne Westgaard; Aasa R Schjølberg; Milada Cvancarova; Tor J Eide; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

10.  Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel.

Authors:  Asif Ali; Victoria Brown; Simon Denley; Nigel B Jamieson; Jennifer P Morton; Colin Nixon; Janet S Graham; Owen J Sansom; C Ross Carter; Colin J McKay; Fraser R Duthie; Karin A Oien
Journal:  BMC Clin Pathol       Date:  2014-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.